Isradipine
This dihydropyridine calcium channel blocker is used to treat high blood pressure by relaxing arterial smooth muscle and reducing peripheral vascular resistance. It selectively blocks L-type calcium channels in blood vessel walls, causing vasodilation without significant effects on cardiac conduction. It has been studied in Parkinson's disease for potential neuroprotective effects.
Berat Molekul
371,4000 g/mol
LogP
4,30
TPSA
104,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Struktur 2D
Cite this structure
Embed this structure
SMILES
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc2nonc12
InChI
InChI=1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
Molecular Formula
C19H21N3O5
HBD / HBA
1 / 8
Ikatan yang Dapat Dirotasi
6
Atom Berat
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
This dihydropyridine calcium channel blocker is used to treat high blood pressure by relaxing arterial smooth muscle and reducing peripheral vascular resistance. It selectively blocks L-type calcium channels in blood vessel walls, causing vasodilation without significant effects on cardiac conduction. It has been studied in Parkinson's disease for potential neuroprotective effects.
Blocks L-type voltage-gated calcium channels in vascular smooth muscle and cardiac myocytes, reducing calcium influx during depolarization. This produces vasodilation, decreased myocardial contractility, and reduced heart rate.
Yes, Isradipine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1648. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3784. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="isradipine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/isradipine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/isradipine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/isradipine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="isradipine"></drugfyi-drug>